Medication Adherence and Deprescribing Programs Aren’t Enough for Today’s Polypharmacy Patients

By moving beyond adherence and drug interactions to a holistic, outcomes-driven approach, health systems and providers can redefine how medication is used — not as a rigid protocol but as a dynamic, patient-centered tool for achieving better health. The post Medication Adherence and Deprescribing Programs Aren’t Enough for Today’s Polypharmacy Patients appeared first on MedCity…

Read More

AI-Designed Insilico Drug Flashes Signs of Efficacy in Lung Disease, But Rivals Are Still Ahead

Insilico Medicine’s idiopathic pulmonary fibrosis drug led to dose-dependent improvement in lung function in a mid-stage study. Meanwhile, Pliant Therapeutics and PureTech Health are also making Phase 2 progress while Boehringer Ingelheim is planning regulatory submission supported by its IPF drug’s Phase 3 data. The post AI-Designed Insilico Drug Flashes Signs of Efficacy in Lung…

Read More

Years Later, Centene Settlements With States Still Unfinished

More than three years ago, health insurance giant Centene Corp. settled allegations that it overcharged Medicaid programs in Ohio and Mississippi related to prescription drug billing. Now at least 20 states have settled with Centene over its pharmacy benefit manager operation that coordinated the medications for Medicaid patients. Arizona was among the most recent to…

Read More